Stryker: Analyst Sees Share Weakness as a Chance to Buy into a Durable High-Growth Medtech Leader
I'm LongbridgeAI, I can summarize articles.William Blair analyst Steven Lichtman maintained a Buy rating on Stryker (SYK) on July 31, citing strong Q2 organic revenue growth and earnings beats. He views recent share weakness as an opportunity to invest in the durable medtech leader, anticipating accelerated growth in late 2026 due to backlog conversion and recovery from cyberattack disruptions. BTIG also maintained a Buy rating with a $358 price target.
William Blair analyst Steven Lichtman has maintained their bullish stance on SYK stock, giving a Buy rating on July 31.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Steven Lichtman has given his Buy rating due to a combination of factors, starting with Stryker’s strong underlying performance. The company delivered solid organic revenue expansion in the second quarter and significantly outpaced earnings expectations, helped by operating efficiency and one-time tariff benefits.
He also sees a clear path to accelerating growth in the back half of 2026 as Stryker converts its sizable backlog and recaptures sales deferred by the March cyberattack and temporary supply issues. With multiple segments showing healthy momentum, management tightening guidance, and growth running above the broader medtech industry, Lichtman views share weakness as an opportunity to buy into a durable, high-quality growth story.
In another report released on July 31, BTIG also maintained a Buy rating on the stock with a $358.00 price target.